2
Clinical Trials associated with Anti-CD19 CAR-T (University of Uppsala)CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy - a Phase II Trial.
Treatment of patients with B cell lymphoma or leukemia with two doses of CD19-targeting chimeric antigen receptor (CAR) T cells to evaluate for safety and efficacy.
CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with B cell lymphoma or leukemia. The CAR consists of a CD19 targeting antibody scFv with three intracellular signaling domains derived from CD3 zeta, CD28 and 4-1BB. Autologous T cells will be gene engineered with the CAR gene using a retrovirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.
100 Clinical Results associated with Anti-CD19 CAR-T (University of Uppsala)
100 Translational Medicine associated with Anti-CD19 CAR-T (University of Uppsala)
100 Patents (Medical) associated with Anti-CD19 CAR-T (University of Uppsala)
100 Deals associated with Anti-CD19 CAR-T (University of Uppsala)